Welcome to our dedicated page for Charles Riv Labs Intl news (Ticker: CRL), a resource for investors and traders seeking the latest updates and insights on Charles Riv Labs Intl stock.
News about Charles River Laboratories International, Inc. (NYSE: CRL) focuses on its role in research and development in biotechnology and its activities as a contract research and manufacturing partner to pharmaceutical, biotechnology, government, and academic clients. Company updates often highlight how Charles River’s research models, discovery and safety assessment services, and manufacturing solutions support the discovery, early-stage development, and safe manufacture of new therapies.
Investors and industry followers can expect frequent news on strategic transactions and partnerships. Recent announcements include planned acquisitions such as K.F. (Cambodia) Ltd., a provider of non-human primates for regulatory-required biomedical, pharmaceutical, and toxicological research, and PathoQuest SAS, a provider of next-generation sequencing solutions for manufacturing quality-control testing. The company also reports collaborations, for example with The Francis Crick Institute on antibody-drug conjugate discovery and with X-Chem, Inc. to expand hit identification capabilities using DNA-encoded library technology.
Charles River’s news flow also covers scientific and operational initiatives. The company has announced the creation of a Scientific Advisory Board led by Dr. Namandjé N. Bumpus to advance New Approach Methodologies (NAMs) and reduce reliance on animal testing, as well as the expansion of its Cell & Gene Therapy Incubator Program to support early-stage advanced therapy developers and enabling technology companies. Updates on its strategic review, portfolio refinement, restructuring initiatives, and capital deployment plans provide additional context on long-term positioning and financial priorities.
Governance and leadership developments are another recurring theme, such as the planned CEO succession and the appointment of a Chief Scientific and Innovation Officer. Earnings releases and conference presentations offer insight into demand trends across the Research Models and Services, Discovery and Safety Assessment, and Manufacturing Solutions segments. For readers tracking CRL, this news page brings together these earnings updates, transaction announcements, scientific collaborations, and strategic milestones in one place.
Charles River Laboratories (NYSE: CRL) announced two planned acquisitions, a senior scientific hire, and a 2026 outlook update at the J.P. Morgan Healthcare Conference. The company agreed to buy K.F. (Cambodia) Ltd. for approximately $510.0 million, expected to be accretive to non-GAAP EPS by ~$0.25 in 2026 and ~$0.60 in 2027. Charles River exercised its option to acquire the remaining 79% of PathoQuest for ~€51.6 million (~$60M); PathoQuest revenue is expected to be ~$15–20M in 2026. Dr. Namandjé N. Bumpus joins as SVP, Chief Scientific and Innovation Officer. Operational notes: DSA net book-to-bill ~1.1x in Q4 2025; 2026 organic revenue growth guidance top end expected to be at least flat; FX to add 100–150 bps to reported growth.
Charles River Laboratories (NYSE: CRL) announced that James C. Foster will retire effective May 5, 2026 at the conclusion of the 2026 Annual Meeting and the Board has unanimously appointed Birgit Girshick, current EVP and COO, as CEO effective in May 2026.
Mr. Foster will remain on the Board as a non-executive director and Martin Mackay will become independent Chair. Foster led Charles River for 30+ years, oversaw 50+ acquisitions, and helped grow revenue from $307M in 2000 to $4.0B in 2024; the company reports working on >80% of FDA-approved drugs since 2017. Girshick has 35+ years at the company and has served as COO since 2021.
Charles River (NYSE: CRL) announced the second cohort of its Cell & Gene Therapy Incubator Program (CIP) on December 11, 2025, completing its 2025 global cohort onboarding and opening applications for 2026.
The six-member cohort includes four advanced therapy developers (CureAge Therapeutics, InterAct Therapeutics, Jaan Biotherapeutics, Kopra Bio) and two enabling technology companies (Grace, HTLab Biowerkli). Participants receive tailored mentorship, regulatory and quality consults, training, and preferential access to Charles River’s global discovery, development, and manufacturing network.
Notable program details: Jaan aims to start clinical testing in 2027, InterAct focuses on AAV8 gene therapy for breast cancer liver metastases, and Kopra has a first development candidate targeting glioblastoma.
Charles River Laboratories (NYSE: CRL) will present at the Evercore 8th Annual Healthcare Conference on Wednesday, December 3, 2025 at 10:00 a.m. ET. Management will provide an overview of the company's strategic focus, business developments, and recent trends. A live webcast will be available via a link posted on the Investor Relations website at ir.criver.com, and a replay will be accessible on the same site for at least two weeks after the presentation.
Charles River Laboratories (NYSE: CRL) will present at the Jefferies Global Healthcare Conference in London on Tuesday, November 18, 2025 at 11:30 a.m. GMT (6:30 a.m. ET). Management will provide an overview of the company's strategic focus, business developments, and recent trends. A live webcast link will be posted on the company's Investor Relations site at ir.criver.com. A replay will be available on the same site after the presentation and will remain accessible for at least two weeks.
Charles River Laboratories (NYSE: CRL) updated investors on a Board-led strategic review and announced actions to sharpen its portfolio, boost efficiency, and prioritize disciplined capital deployment.
Key moves: targeted sales of underperforming or non-core businesses representing approximately 7% of estimated 2025 revenue; projected non-GAAP EPS accretion of at least $0.30 annually from divestitures; cumulative restructuring savings of about $225 million annualized in 2026 plus incremental $70 million net cost savings; and a new $1.0 billion share repurchase authorization (the company repurchased $450.7 million since August 2024). Management will provide a fuller update at an Investor Day in 2026.
Charles River Laboratories (NYSE: CRL) reported Q3 2025 revenue of $1.00 billion, down 0.5% year-over-year, with organic revenue down 1.6%. GAAP net income available to common shareholders was $54.4 million or $1.10 GAAP EPS, versus $1.33 a year ago. Non-GAAP net income was $120.3 million and $2.43 non-GAAP EPS, declines of 10.0% and 6.2% respectively. Segment highlights: RMS revenue +7.9%, DSA revenue $600.7 million (-2.3%), Manufacturing revenue $190.7 million (-3.1%).
The company updated 2025 guidance: non-GAAP EPS $10.10–$10.30 and reported revenue change of (1.5)%–(0.5)%, and cited venture investment losses of $0.50 in full-year guidance. A live webcast is scheduled for November 5, 2025 at 9:00 a.m. ET.
Charles River (NYSE: CRL) and The Francis Crick Institute announced a collaboration on Antibody-Drug Conjugate (ADC) discovery and development on October 22, 2025. The agreement creates an integrated, end-to-end workflow spanning antibody discovery, conjugation, in vitro profiling, and preclinical studies, jointly managed to shorten timelines and improve efficiency.
The collaboration will use phage display libraries for high-affinity, target-specific antibodies and Charles River’s Retrogenix in vitro profiling platform to assess off-target interactions and enhance early safety evaluation.
Charles River (NYSE:CRL) announced a strategic collaboration with X-Chem on October 20, 2025 to expand hit identification capabilities by offering clients access to X-Chem’s DNA-encoded library (DEL) platform, which comprises a proprietary library of over 15 billion compounds. The partnership pairs Charles River’s protein production, assay development, and hit ID expertise with X-Chem’s DEL screening and data analysis to create an end-to-end workflow from hit identification to Hit-to-Lead optimization.
The collaboration is positioned to provide scalable, data-driven hit-finding options for biotech and pharma discovery programs and to broaden access to DEL screening through Charles River’s services.
Charles River (NYSE: CRL) announced a global Scientific Advisory Board, led by Dr. Namandjé N. Bumpus, to accelerate adoption of New Approach Methodologies (NAMs) for non-clinical safety and efficacy testing, aiming to reduce animal use.
The interdisciplinary board will embed in vitro, in silico, and in chemico methods across therapeutic, preventive, and chemical testing and support regulatory acceptance and commercial deployment. Examples cited include Endosafe Trillium, in vitro skin sensitization assays, virtual control groups, Logica, and NGS services.